QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pa... ( Establishes Preferred Dose for Op...)

Navigation Links

Biology News Medicine News Biology Products Medicine Products Biology Definition Medicine Definition Biology Technology Medicine Technology Biology Dictionary Medicine Dictionary

HOME >> MEDICINE >> TECHNOLOGY

QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pain Therapy

Date:5/22/2008

Establishes Preferred Dose for Optimal Efficacy and Tolerability; Study Goals and Secondary Endpoints Met

SYDNEY, Australia and BEDMINSTER, N.J., May 22 /PRNewswire-FirstCall/ -- QRxPharma Limited (ASX: QRX), a clinical-stage specialty pharmaceutical company focused on the development and commercialisation of therapies for pain and central nervous system (CNS) disorders, announced today additional Phase 3 data for Q8003IR establishing a 12mg/8mg morphine and oxycodone combination as the preferred dose for optimal efficacy and tolerability.

"While the initial Phase 3 efficacy data demonstrated statistically significant pain reduction activity of Q8003IR at all dose levels, further analysis suggests that the 12mg/8mg dose delivers the best analgesic effect and tolerability profile," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma. "These data confirm that our patented dual opioid combination of morphine and oxycodone provides synergistic effects on pain relief and is able to achieve equal or better analgesia at materially lower doses than the active opioid comparator while simultaneously reducing incidence levels of specific side effects."

The goal of the double-blind, placebo-controlled Phase 3 study was to compare four different dosage regimens of Q8003IR in patients with moderate to severe post-surgery pain (bunionectomy) and establish the preferred dose parameters. Secondary endpoints included: (1) efficacy relating to the time to onset of analgesia and the duration of effect from a single oral dose and (2) safety as measured by the incidence and intensity of opioid-related adverse events.

Of the patients receiving 12mg/8mg dose of morphine/oxycodone, 58% reported good to excellent global improvement (as compared to 13% for placebo) and demonstrated the greatest dose-response effect (p<0.0003) in terms of reducing pain intensity scores as well as other measures of analgesic effect.

Post-
'/>"/>

SOURCE QRxPharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
2. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
3. CenterWatch Releases State of the Clinical Trials Industry 2008 - A Key Industry Resource for Market Research and Competitive Intelligence
4. Immunosyn Releases Wound Healing Photographs From the First Phase Proof of Concept Trial in Europe for Treatment of Diabetic Ulcers With Biopharmeceutical SF-1019
5. TCS Healthcare Technologies Releases Three New Clinical Care Programs Within ACUITY
6. Immunosyn Corporation Releases SF-1019 Study Results
7. Cardinal Health Releases New Tool to Combat MRSA Infections in Hospitals
8. AcroMetrix Releases New OptiQuant(R) HIV-1 Quantification Panel
9. CEL-SCI Corporation Releases Letter to Shareholders
10. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
11. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial

Post Your Comments:

[0] Helix BioPharma Corp. Announces Fiscal Q1 2010 Results [0] Roper Industries Completes the Acquisition of Verathon, Inc.[0] Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities

Other Medicine Technology:Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials 2 Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials 3 Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials 4 Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials 5 Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials 6 Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development 2

Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials Breakthrough Large Scale Transfection Technology Accelerates Cell-Based Assay Development

Breaking Medicine News(10 mins):Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 2 Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 3 Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 4 Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 5 Health News:You Never Get a Second Chance to Make a First Impression: High-Definition for the Web 2 Health News:Dr. 90210 Rhinoplasty Specialist Now Accommodates Both the East and West Coast 2 Health News:World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins 2 Health News:World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins 3 Health News:Perkins: Senate Would Rather Mandate Abortion Funding Than Enact 'Health Care Reform' 2

[0] The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility"[0] You Never Get a Second Chance to Make a First Impression: High-Definition for the Web [0] Dr. 90210 Rhinoplasty Specialist Now Accommodates Both the East and West Coast [0] World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins [1] Perkins: Senate Would Rather Mandate Abortion Funding Than Enact 'Health Care Reform'

Duane Reade Holdings, Inc. Reports Fourth Quarter and Full Year 2008 Results World's Most Advanced Foot Scanning Kiosk Made Available to Retailers by eSoles and Pressure Profile Systems, Inc.USPTO Issues Notice of Final Determination for Patent Term Extension for NAMENDA(R)Obio Pharmaceutical Announced New Antiviral Drug Discovery to Combat Influenza Virus Career Step Announces New Executive Team Adventist Midwest Health Engages Medium Blue Search Engine Marketing in Geographically-Targeted SEO Campaign

Medicine Products:

BET/1P-ERB - Tubular Base - Model 1P62-ERB BET/1P-ERB - Tubular Base - Model 1P61-R-ERB BET/1P-ERB - Tubular Base - Model 1P58-R-ERB BET/1P-ERB - Tubular Base - Model 1P57-R-ERB

QRxPharma Releases Additional Phase 3 Data for Q8003IR 'Dual Opioid' Pa...( Establishes Preferred Dose for Op...),Health